Biotech ExpreS2ion Biotechnologies - that develops vaccines for covid-19, breast cancer, influenza and malaria - is currently conducting a rights issue of 73 million SEK. CEO Bent U. Frandsen visited BioStock's studio to give a status update on the covid-19 project, which is being developed together with Bavarian Nordic, and to tell us more about the rights issue.

Watch the interview at biostock.se:

https://www.biostock.se/en/2022/04/biostock-studio-expres2ions-ceo-gives-status-update/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/expres2ion-biotechnologies/r/biostock-studio--expres2ion-s-ceo-gives-status-update,c3549897

(c) 2022 Cision. All rights reserved., source Press Releases - English